EGFR and head and neck squamous cell carcinoma: The limitations of therapies targeting programmed death receptor 1 (PD-1) and EGFR, as well as the strong adverse effects of standard treatments, necessitate the development of new, safer treatments for R/M HNSCC [4,11,31].